Mapping the evidence on interactions between Complementary and Alternative Medicines with conventional antituberculosis medicines in the sub-Sahara African countries: A Scoping Review Protocol

Abstract

Abstract Background: Complementary and Alternative Medicines (CAM) with their different bioactive compounds are commonly used either alone or in combination with conventional medicines in the treatment of tuberculosis and have proven clinically pharmacological activities. Pharmacokinetic interaction are the results of the combination of Complementary and Alternative Medicines with conventional medicines or intrinsically linked to the inhibition of the metabolic enzymes responsible for the metabolism and clearance of the drugs amongst patients. This study aims at mapping the evidence on documented interactions from the combination of Complementary and Alternative Medicines with antituberculosis medicines in the sub-Sahara African countries Methods/design: This study will be done following recommendations of Levac et al. (Implement Sci 5:69, 2010) and the framework made by Arksey and O’Malley. Based on our eligibility criteria, the appropriate literature will be searched in the following databases: World Health Organization, Google Scholar, PubMed, Science Direct, Open Access Theses and Dissertations and EBSCOhost which includes: Newspaper Source, Academic Search Complete and MEDLINE. Relevant studies published from 2005 to December 2020 will be included. Eligible studies should show evidence on documented interactions from the combination CAM with antituberculosis medicines and any interactions as outcomes. NVIVO software will be used to draw out the pertinent thematic analysis and outcomes of the research. Stata statistical software (Stata Corp V.14, TX, USA) will be used for analysing quantitative data, while the chi-squared test on Cochran’s Q statistic will be used to evaluate the Heterogeneity that will be quantified by I2 values. The χ2 test on Cochrane’s Q statistic will be used to detect any heterogeneity between subgroups. Discussion: This review anticipates finding relevant publications reporting the evidence on documented interactions from the combination of CAM with antituberculosis medicines in Sub-Saharan African countries. The synthesis of this obviousness base will serve as guidance for future research studies. The result from the research will be printed and electronically exposed via traditional academic platforms, namely peer-reviewed publications and at conference presentations. Systematic review Prospero registration number: CRD42022329684